Biology of prostate-specific antigen.
Lilja, Hans LU
(2003)
In Urology
62(5 Suppl 1).
p.27-33
- Abstract
- The human kallikrein (hk) family, located on chromosome 19, encodes prostate-specific antigen (PSA [or hK3]), hK2, hK4, and hK15 (prostin), as well as other serine proteases. Although PSA has been used in the detection of prostate cancer for several years, much remains unknown about its function and forms. The regulatory mechanisms of PSA are vital to its understanding. A particular mechanism by which PSA forms complexes with either alpha(1)-antichymotrypsin or alpha(2)-macroglobulin may provide important information for disease detection and progression. Data are emerging that show that active hK2, hK4, and hK15 may be important to convert pro-PSA to the active PSA enzyme. This information, along with insights into the precise mechanisms... (More)
- The human kallikrein (hk) family, located on chromosome 19, encodes prostate-specific antigen (PSA [or hK3]), hK2, hK4, and hK15 (prostin), as well as other serine proteases. Although PSA has been used in the detection of prostate cancer for several years, much remains unknown about its function and forms. The regulatory mechanisms of PSA are vital to its understanding. A particular mechanism by which PSA forms complexes with either alpha(1)-antichymotrypsin or alpha(2)-macroglobulin may provide important information for disease detection and progression. Data are emerging that show that active hK2, hK4, and hK15 may be important to convert pro-PSA to the active PSA enzyme. This information, along with insights into the precise mechanisms of PSA expression, may be used to suggest that PSA and, perhaps, other members of the hK family contribute critical control mechanisms to tumor invasion or progression. Although much remains to be revealed on the role of these gene products in the detection and progression of prostate cancer, findings from studies that show sensitive signaling of the disease greater than or equal to20 years before the diagnosis of clinically significant prostate cancer may alter screening procedures and improve treatment options. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/119077
- author
- Lilja, Hans
LU
- organization
- publishing date
- 2003
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Urology
- volume
- 62
- issue
- 5 Suppl 1
- pages
- 27 - 33
- publisher
- Elsevier
- external identifiers
-
- pmid:14607215
- wos:000186465500005
- scopus:0242523062
- ISSN
- 1527-9995
- DOI
- 10.1016/S0090-4295(03)00775-1
- language
- English
- LU publication?
- yes
- id
- cd58e81f-801b-4aee-8846-646dc69104df (old id 119077)
- alternative location
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14607215&dopt=Abstract
- date added to LUP
- 2016-04-01 11:59:57
- date last changed
- 2022-05-18 23:44:17
@article{cd58e81f-801b-4aee-8846-646dc69104df,
abstract = {{The human kallikrein (hk) family, located on chromosome 19, encodes prostate-specific antigen (PSA [or hK3]), hK2, hK4, and hK15 (prostin), as well as other serine proteases. Although PSA has been used in the detection of prostate cancer for several years, much remains unknown about its function and forms. The regulatory mechanisms of PSA are vital to its understanding. A particular mechanism by which PSA forms complexes with either alpha(1)-antichymotrypsin or alpha(2)-macroglobulin may provide important information for disease detection and progression. Data are emerging that show that active hK2, hK4, and hK15 may be important to convert pro-PSA to the active PSA enzyme. This information, along with insights into the precise mechanisms of PSA expression, may be used to suggest that PSA and, perhaps, other members of the hK family contribute critical control mechanisms to tumor invasion or progression. Although much remains to be revealed on the role of these gene products in the detection and progression of prostate cancer, findings from studies that show sensitive signaling of the disease greater than or equal to20 years before the diagnosis of clinically significant prostate cancer may alter screening procedures and improve treatment options.}},
author = {{Lilja, Hans}},
issn = {{1527-9995}},
language = {{eng}},
number = {{5 Suppl 1}},
pages = {{27--33}},
publisher = {{Elsevier}},
series = {{Urology}},
title = {{Biology of prostate-specific antigen.}},
url = {{http://dx.doi.org/10.1016/S0090-4295(03)00775-1}},
doi = {{10.1016/S0090-4295(03)00775-1}},
volume = {{62}},
year = {{2003}},
}